Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

BACKGROUND: Isatuximab (Isa), an anti‐CD38 monoclonal antibody, and carfilzomib (K), a next‐generation proteasome inhibitor (PI), both have potent single‐agent activity in relapsed and refractory multiple myeloma (RRMM). METHODS: This phase 1b study evaluated the combination of Isa and K in 33 patie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Martin, Thomas G., Shah, Nina, Richter, Joshua, Vesole, David H., Wong, Sandy W., Huang, Chiung‐Yu, Madduri, Deepu, Jagannath, Sundar, Siegel, David S., Biran, Noa, Wolf, Jeffrey L., Parekh, Samir, Cho, Hearn J., Munster, Pamela, Richard, Shambavi, Ziti‐Ljajic, Samira, Chari, Ajai
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252002/
https://ncbi.nlm.nih.gov/pubmed/33735504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33448
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars